Nufarm (ASX:NUF)- CEO, Greg Hunt
CEO, Greg Hunt
Source: Nufarm
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • The US Food and Drug Administration (FDA) recognises Nufarm’s (NUF) Nuseed omega-3 canola oil as a new dietary ingredient
  • The company has created a plant-based source of omega-3 fatty acids as an alternative to fish oil, the most common source of omega-3
  • According to NUF, the oil will help reduce pressure on wild-fish stocks
  • CEO Greg Hunt said FDA approval is a huge milestone for the company
  • On market close for the day, Nufarm was up 3.21 per cent and is trading at $4.50 per share

The US Food and Drug Administration (FDA) has recognised Nufarm’s (NUF) Nuseed omega-3 canola oil as a new dietary ingredient.

The company has created a plant-based source of omega-3 fatty acids and is an alternative to fish oil, the most common source of omega-3.

Omega-3 have several health benefits, such as lowering blood pressure and raising.

Nuseed’s omega-3 canola helps fill the gap between how much long-chain omega-3 is needed to support human and animal nutrition and how little the ocean can sustainably provide.

CEO Greg Hunt said FDA approval is a huge milestone for the company.

“The FDA’s acknowledgment along with our recently completed human clinical trial, allows us to progress our plans to expand into the human nutrition market and meet a growing demand for plant-based omega-3 essential oil options,” Mr Hunt said.

“With FDA recognition of Nuseed’s conclusion that Nutriterra is a safe new dietary ingredient, we are well placed to secure commercial partnerships that will attract new consumers, enter into new segments and raise consumption of omega-3.”

Notably, a human trial was conducted with the omega-3 canola oil and showed participants absorbing the oil’s omega-3s.

On market close for the day, Nufarm was up 3.21 per cent and is trading at $4.50 per share.

NUF by the numbers
More From The Market Online

Market shrugs as Fisher & Paykel announces mass recall

Fisher & Paykel has initiated a voluntary limited recall of batches of Airvo 1 and my…
The Market Online Video

Brian Leedman’s BlinkLab to join ASX: AI-driven smartphone app screens for autism, ADHD

BlinkLab is a world-first, AI-driven digital healthcare venture, that uses a smartphone and facial recognition to…

Osteopore stock spikes 900% on Singapore and Vietnam approvals

Osteopore's (ASX:OSX) share price was up 38% after the regenerative medicine company received approval for its…

Amplia Therapeutics takes step up in pancreatic cancer treatment

Amplia Therapeutics is on to next step in its pancreatic cancer treatment research after a successful…